About
Menten AI is a biotechnology company that combines quantum computing, artificial intelligence, and protein engineering to change drug discovery and design. Founded in 2018 by CEO Vikram Mulligan and drawing on research from the Baker Lab at the University of Washington, it uses quantum-enhanced algorithms to solve complex protein folding and design problems that are computationally intractable for classical computers. The company's platform designs novel protein therapeutics, including peptides and small proteins, by exploring vast sequence spaces and optimizing for properties such as stability, specificity, and manufacturability. Its quantum computing approach offers advantages in sampling complex conformational states and solving the multi-objective design problems inherent in drug discovery. Menten AI has developed a pipeline of proprietary therapeutic candidates and offers computational design services to pharmaceutical partners. Its technology brings together quantum computing and biotechnology with the goal of accelerating the development of new medicines for diseases including cancer, autoimmune disorders, and infectious diseases.
Quantum Specifications
| Quantum Focus | software |